Developing early formulations: Practice and perspective

International Journal of Pharmaceutics

Volumn 341, Issue 1-2, 2007, Pages 1-19

  Li, Ping ^a   Zhao, Luwei ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b SANOFI   (France)

Author keywords

Animal formulations; Early formulations; Poorly water soluble drugs; Solubility enhancement

Indexed keywords

ACETIC ACID; ALCOHOL; BICARBONATE; BUFFER; CITRIC ACID; CREMOPHOR; CYCLODEXTRIN; EXCIPIENT; HYDROCHLORIC ACID; LACTIC ACID; LIPID; LIPOSOME; MACROGOL 400; MALEIC ACID; MIGLYOL; OCTANOIN; PHOSPHATIDYLCHOLINE; POLYMER; SODIUM DIHYDROGEN PHOSPHATE; SODIUM HYDROXIDE; SOLVENT; SOYBEAN OIL; SURFACTANT; TARTARIC ACID;

BIOAVAILABILITY; DISPERSION; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; HUMAN; IN VITRO STUDY; KINETICS; MAXIMUM TOLERATED DOSE; MICROEMULSION; NONHUMAN; PH MEASUREMENT; PRECIPITATION; PRIORITY JOURNAL; REVIEW; SCREENING; SOLUTION AND SOLUBILITY; SUSPENSION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; EXCIPIENTS; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 34447646495     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.05.049     Document Type: Review

References (78)

1. Armstrong N.A., and James K.C. Drug release from lipid based dosage forms. II. Int. J. Pharm. 6 (1980) 195-204
2. Albers E., and Muller B.W. Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 311-337
3. Attwood D., and Florence A.T. Surfactant Systems, Their Chemistry, Pharmacy and Biology (1983), Chapman and Hall, London, England
4. Betageri G.V., Jenkins S.A., and Parsons D.L. Liposome Drug Delivery Systems (1993), Technomic Publishing Company Inc., USA, Lancaster, Pennsylvania
5. Betageri G.V., and Parsons D.L. Drug encapsulation and release from multilamellar and unilamellar liposomes. Int. J. Pharm. 81 (1992) 235-241
6. Bittner B., and Mountfield R.J. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr. Opin. Drug Discov. Dev. 5 (2002) 59-71
7. Chiou W.L., and Riegelman S. Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J. Pharm. Sci. 58 (1969) 1505-1509
8. Cirri M., Maestrelli F., Corti G., Furlanetto S., and Mura P. Simultaneous effect of cyclodextrin complexation, pH, and hydrophilic polymers on naproxen solubilization. J. Pharm. Biomed. Anal. 42 (2006) 126-131
9. Charman W.N. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J. Pharm. Sci. 89 (2000) 967-978
10. Connors K.A., Amidon G.L., and Stella V.J. Chemical Stability of Pharmaceuticals. 2nd ed. (1986), John Wiley & Sons, New York
11. Davies B., and Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10 (1993) 1093-1095
12. Dearden J.C., and Rahman M.H. QSAR approach to the prediction of melting points of substituted anilines. Math. Comput. Model. 11 (1988) 843
13. Gao P., and Morozowich W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Exp. Opin. Drug Deliv. 3 (2006) 97-110
14. Hansch C., and Leo A.J. Substituent Constants for Correlation Analysis in Chemistry and Biology (1979), Wiley, New York, NY
15. Higuchi T., and Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Inst. 4 (1965) 117-212
16. Humberstone A.J., and Charman W.N. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 25 (1997) 103-128
17. Humbert H. Variability of the bioavailability of cyclosporine: benefit of the Neoral formulation. Therapie 52 (1997) 353-357 (in French)
18. Irie T., and Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicology issues and safety evaluations. J. Pharm. Sci. 86 (1997) 147-162
19. Irwin W.J., and Iqbal M. Bropirimine formulation: the dynamic testing of injections. Int. J. Pharm. 83 (1992) 241-249
20. Jain A., Ran Y., and Yalkowsky S.H. Effect of pH-sodium lauryl sulfate combination on solubilization of PG-300995 (an anti-HIV agent): a technical note. AAPS PharmSciTech. 5. (2004)
21. Jain N., and Yalkowsky S.H. Estimation of the aqueous solubility. I. Application to organic nonelectrolytes. J. Pharm. Sci. 90 (2001) 234-252
22. Johnson M.D., Hoesterey B.L., and Anderson B.D. Solubilization of a tripeptide HIV protease inhibitor using a combination of ionization and complexation with chemically modified cyclodextrins. J. Pharm. Sci. 8 (1994) 1142-1146
23. Kaus, L., 1998. Buffers and buffering agents. In: Swarbrick, J., Boylan, J.C. (Eds.), Encyclopedia of Pharmaceutical Technology, vol. 2, pp. 213-231.
24. Krzyzaniak J.F., Myrdal P.B., Simamora P., and Yalkowsky S.H. Boiling point and melting point prediction for aliphatic, non-hydrogen bonding compounds. Ind. Eng. Chem. Res. 34 (1995) 2530
25. Langner M., and Kral T.E. Liposome-based drug delivery systems. Pol. J. Pharamacol. 51 (1999) 211-222
26. Lasic D.D. Liposomes: From Physics to Applications (1993), Elsevier, Amsterdam, London
27. Lee Y.-C., Zocharski P., and Samas B. An intravenous formulation decision tree for discovery compound formulation development. Int. J. Pharm. 253 (2003) 111-119
28. Li P., Patel H., Tabibi S.E., Vishnuvajjala R., and Yalkowsky S.H. Evaluation of intravenous flavopiridol formulations. PDA J. Pharm. Sci. Technol. 53 (1999) 137-140
29. Li P., Tabibi S.E., and Yalkowsky S.H. Solubilization of flavopiridol by pH control combined with cosolvents, surfactants, or complexants. J. Pharm. Sci. 88 (1999) 945-947
30. Li P., Tabibi S.E., and Yalkowsky S.H. Combined effect of complexation and pH on solubilization. J. Pharm. Sci. 87 (1998) 1535-1537
31. Li P., Tabibi S.E., and Yalkowsky S.H. Solubilization of Ionized and Un-ionized Flavopiridol by Ethanol and Polysorbate 20. J. Pharm. Sci. 88 (1999) 507-509
32. Li P., and Zhao L. Solubilization of flurbiprofen in pH-surfactant solutions. J. Pharm. Sci. 92 (2003) 951-956
33. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
34. Liu F.-Y., Kildsig D.O., and Mitra A.K. Cyclodextrin/weak-electrolyte complexation: interpretation and estimation of association constants from phase solubility diagrams. Pharm. Res. 9 (1992) 1671-1672
35. Liversidge, G.G., Cundy, K.C., Bishop, J., Czekai, D., 1991. Surface Modified Drug Nanoparticles. US Patent 5145684.
36. Loftsson T., Fridriksdottir H., and Gudmundsdottir T.K. The effect of water-soluble polymers on aqueous solubility of drugs. Int. J. Pharm. 127 (1996) 293-296
37. Loftsson T., and Fridriksdottir H. The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin. Int. J. Pharm. 163 (1998) 115-121
38. Loftsson T., and Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85 (1996) 1017-1025
39. Loftsson T., Fridfriksdottir H., Sigurdardottir A.M., and Ueda H. The effect of water-soluble polymers on drug-cyclodextrin complexation. Int. J. Pharm. 110 (1994) 169-177
40. Lorenze W., Reimann H.J., Schmal A., Dormann P., and Schwarz B. Histamine release in dogs by cremophor EL and its derivates: oxethylated oleic acid is the most effective constituent. Agents Actions 7 (1977) 63-67
41. Ma D.Q., Rajewski R.A., Vander V.D., and Stella V.J. Comparative effects of (SBE)7m-beta-CD and HP-beta-CD on the stability of two anti-neoplastic agents, melphalan and carmustine. J. Pharm. Sci. 89 (2000) 275-287
42. Malmsten M. Surfactants and Polymers in Drug Delivery (2002), Marcel Dekker
43. Matsunaga N., Nakamura K., Yamamoto A., Taguchi E., Tsunoda H., and Takahashi K. Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window. Mol. Cancer Ther. 5 (2006) 80-88
44. Medlicott N.J., Foster K.A., Audus K.L., Gupta S., and Stella V.J. Comparison of the effects of potential parenteral vehicles for poorly water-soluble anticancer drugs (organic co-solvents and cyclodextrin solutions) on cultured endothelial cells (HUV-EC). J. Pharm. Sci. 87 (1998) 1138-1143
45. Okimoto K., Rajewski R.A., Uekama K., Jona J.A., and Stella V.J. The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE-β-CD) β-cyclodextrins. Pharm. Res. 13 (1996) 256-264
46. Physicians' Desk Reference, 57th ed., 2003. Medical Economics Company Inc.
47. Pollard S., Nashan B., Johnston A., Hoyer P., Belitsky P., Keown P., and Helderman H. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clin. Therap. 25 (2003) 1654-1669
48. Porter C.J.H., and Charman W.N. Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J. Receptors Signal Trans. 21 (2001) 215-257
49. Pouton C.W. Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification. Int. J. Pharm. 27 (1985) 335-348
50. Rajewski R.A., and Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85 (1996) 1142-1169
51. Ran Y.Q., and Yalkowsky S.H. Halothane, a novel solvent for the preparation of liposomes containing 2-4′-amino-3′-methylphenyl benzothiazole (AMPB), an anticancer drug: a technical note. e-Journal: AAPS PharmSciTech. 4 (2003)
52. Redenti E., Szente L., and Szejtli J. Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J. Pharm. Sci. 89 (2000) 1-8
53. Redenti E., Szente L., and Szejtli J. Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. J. Pharm. Sci. 90 (2001) 979-986
54. Remington: The Science and Practice of Pharmacy, 20th ed., 2000. In: Gennaro, A.R. (Ed.). Lippincott Williams & Wilkins.
55. Rowe R.C., Sheskey P.J., and Weller P.J. Handbook of Pharmaceutical Excipients. 4th ed. (2003), Pharmaceutical Press & American Pharmaceutical Association
56. Sekiguchi K., and Obi N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 9 (1961) 866-872
57. Serajuddin A.T.M., Sheen P.C., Mufson D., Bernstein D.F., and Augustine M.A. Effect of vehicle amphiphilicity on the dissolution and bioavailability of the poorly water-soluble drug from solid dispersion. J. Pharm. Sci. (1988) 414-417
58. Shen H.R., and Zhong M.K. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J. Pharm. Pharmacol. 58 (2006) 1183-1191
59. Simamora P., Pinsuwan S., Alvarez J.M., Myrdal P.B., and Yalkowsky S.H. Effect of pH on injection phlebitis. J. Pharm. Sci. 84 (1995) 520-522
60. Simamora P., Pinsuwan S., Surakitbanharn Y., and Yalkowsky S.H. Studies in phlebitis. VIII. Evaluations of pH solubilized intravenous dexverapamil formulations. PDA J. Pharm. Sci. Technol. 50 (1996) 123-128
61. Simonelli A.P., Mehta S.C., and Higuchi W.I. Dissolution rates of high energy poly(vinylpyrrolidone) (PVP)-sulfathiazole co-precipitates. J. Pharm. Sci. 58 (1969) 538-549
62. Strickley R.G. Solubilizing excipients in oral and injectable. Pharm. Res. 21 (2004) 201-230
63. Surakitbanharn Y., Simamora P., Ward G.H., and Yalkowsky S.H. Precipitation of pH solubilized phenytoin. Int. J. Pharm. 109 (1994) 27-33
64. Sweetana S., and Akers M.J. Solubility principles and practices for parenteral drug dosage form development. PDA J. Pharm. Sci. Technol. 50 (1996) 330-342
65. Tinwalla A.Y., Hoesterey B.L., Xiang T.-X., Lim K., and Anderson B.D. Solubilization of thiazolobenzimidazole using a combination of pH adjustment andcomplexation with 2-hydroxylpropyl-β-cyclodextrin. Pharm. Res. 10 (1993) 1136-1143
66. Thompson D.O. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. 14 (1997) 1-104
67. Uchenna Agu R., Jorissen M., Willems T., Van den Mooter G., Kinget R., Verbeke N., and Augustijns P. Safety assessment of selected cyclodextrins-effect on ciliary activity using a human cell suspension culture model exhibiting in vitro ciliogenesis. Int. J. Pharm. 193 (2005) 219-226
68. Wang Y.-C.J., and Kowal R.R. Review of excipients and pH's for parenteral products used in the United States. J. Parenteral Drug Assoc. 34 (1980) 452-462
69. Ward G.H., and Yalkowsky S.H. Studies in phlebitis. VI. Dilution-induced precipitation of amiodarone-HCl. J. Parenteral. Sci. Technol. 47 (1993) 161-165
70. Wiedmann T.S., and Kamel L. Examination of the solubilization of drugs by bile salt micelles. J. Pharm. Sci. 91 (2002) 1743-1764
71. Yalkowsky S.H. Solubility and Solubilization in Aqueous Media (1999), Oxford University Press
72. Yalkowsky S.H., and Valvani S.C. Solubility and partitioning. I. Solubility of nonelectrolytes in water. J. Pharm. Sci. 69 (1980) 912-922
73. Yalkowsky S.H., and Valvani S.C. Precipitation of solubilized drugs due to injection or dilution. Drug Intell. Clin. Pharm. 11 (1977) 417-419
74. Yalkowsky S.H., Krzyzaniak J.F., and Ward G.H. Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 87 (1998) 787-796
75. Zhao L., Li P., and Yalkowsky S.H. Solubilization of fluasterone. J. Pharm. Sci. 88 (1999) 967-969
76. Zhao L., Ran Y., Tabibi E., and Yalkowsky S.H. Formulation and stability evaluation of stealth liposomes containing the antitumor agent 2-(4′-amino-3′-methylphenyl)-benzothiazole, NSC674495 (AMPB). Clin. Cancer Res. 6 (2000) 4556S-4556S (Suppl. November)
77. Zhao L., Orton E., and Vemuri N.M. Predicting solubility in multiple non-polar drugs/cyclodextrin system. J. Pharm. Sci. 91 (2002) 2301-2306
78. Zhao L., and Yalkowsky S.H. A combined group contribution and molecular geometry approach for predicting melting points of aliphatic compounds. Ind. Eng. Chem. Res. 38 (1999) 3581-3584